Abstract
A pandemic of 2019 novel coronavirus diseases (COVID-19) outbreak is a
major public health emergency that has spread in the fastest speed, and
caused the most extensive infection world widely. Transbronchial biopsy
(TBB) and computed tomography guided percutaneous needle biopsy (CTPNB)
is the most common and significant method for the diagnosis of lung
cancer. During the COVID-19 pandemic, the indications of TBB and CTPNB
must be managed strictly. Therefore, it is extremely indispensable to
perform meticulous and individualized management for lung cancer
patients to protect the patients from COVID-19.